Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

June’s top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200

Bayer reported positive results from the Phase III RESORCE trial of Stivarga (regorafenib) tablets to treat unresectable hepatocellular carcinoma, and TapImmune initiated its Phase II trial of cancer vaccine TPIV 200. Drugdevelopment-technology.com wraps up the key headlines from June 2016.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free


Go Top